Aptus Capital Advisors LLC Sells 1,205 Shares of IDEXX Laboratories, Inc. $IDXX

Aptus Capital Advisors LLC lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,587 shares of the company’s stock after selling 1,205 shares during the period. Aptus Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $7,403,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $31,000. Armstrong Advisory Group Inc. increased its stake in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares during the period. Salomon & Ludwin LLC bought a new stake in IDEXX Laboratories in the third quarter valued at about $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new position in IDEXX Laboratories in the third quarter worth about $35,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $608.41 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The firm has a market cap of $48.44 billion, a PE ratio of 46.55, a price-to-earnings-growth ratio of 3.70 and a beta of 1.66. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company’s 50-day moving average price is $666.94 and its two-hundred day moving average price is $668.42.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm earned $2.53 earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, BTIG Research lowered their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Buying and Selling

In related news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This represents a 53.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last 90 days. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.